Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:22:22.714Z.
Calculation as of: 2026-10-06T17:22:22.714Z.
Quote observation: 2026-10-06T17:20:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa669979e2b3f995ef920df13c3a539cab2f3704a4556e475e3dd75e53b0e3a2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Kestra Medical Technologies, Ltd.
Market Cap
$1.60B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.59B
EV/EBIT Ratio
25.47x
TTM Avg
110.32x
3Y Avg
127.60x
5Y Avg
102.82x
Market Cap
$1.62B
EV/EBIT Ratio
10.56x
TTM Avg
32.14x
3Y Avg
262.80x
5Y Avg
252.98x
Market Cap
$1.64B
EV/EBIT Ratio
N/A
TTM Avg
33.08x
3Y Avg
33.08x
5Y Avg
33.08x
Market Cap
$1.54B
EV/EBIT Ratio
N/A
TTM Avg
449.30x
3Y Avg
449.30x
5Y Avg
449.30x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd. (KMTS) | $1.60B | N/A | N/A | N/A | N/A |
| Omnicell, Inc. (OMCL)vs › | $1.59B | 25.47x | 110.32x | 127.60x | 102.82x |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | N/A | N/A | N/A | N/A |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 10.56x | 32.14x | 262.80x | 252.98x |
| Septerna Inc (SEPN)vs › | $1.63B | N/A | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.64B | N/A | 33.08x | 33.08x | 33.08x |
| Innoviva, Inc. (INVA)vs › | $1.54B | 7.65x | 117.97x | 74.38x | 44.05x |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | N/A | 449.30x | 449.30x | 449.30x |
| Nutex Health, Inc. (NUTX)vs › | $1.53B | 4.59x | 3.98x | 4.35x | 10.88x |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.53B | N/A | 40.24x | 40.24x | 40.24x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
